期刊文献+

HPLC测定盐酸齐拉西酮血药浓度

Determination of Ziprasidne Hydrochloride Concentrations in Plasma by HPLC
原文传递
导出
摘要 目的建立盐酸齐拉西酮血药浓度的测定方法。方法采用反相高效液相色谱法测定盐酸齐拉西酮血药浓度,色谱柱采用Kromasil C18(4.6 mm×250 mm,5μm),流动相:甲醇-乙腈-40 mmol.L-1乙酸铵溶液(用乙酸调节pH值至3.50±0.1)(100∶100∶155);流速:1.0 mL·min^-1;内标:卡马西平;检测波长:254 nm。结果以盐酸齐拉西酮与内标物峰面积之比(Y)对盐酸齐拉西酮血清浓度(C)进行线性回归,得回归方程:C=213Y-85.5(r=0.996 2),表明本法在20.0~1 200μg.L-1内线性关系良好,平均加样回收率为97.4%。结论本法操作简便、结果准确,可以用于临床盐酸齐拉西酮血药浓度的测定。 OBJECTIVE To develop an HPLC method for the quantitative determination of ziprasidne hydrochloride in plasma.METHODS The residues were analyzed with a RP-HPLC used Kromasil C18 column(4.6 mm×250 mm,5 μm) with the mobile phase consisted of methanol-acetonitrile-40 mmol.L-1 ammonium acetate(With acetic acid adjust to pH 3.5±0.1)(100 ∶ 100 ∶ 155).The flow rate was 1.0 mL·min^-1,and carbamazepine was used as internal standard.The detection wavelength was set at 254 nm.RESULTS Linear regression analysis was made by ziprasidne hydrochloride plasma concentration(C) and the peak area ratio(Y) of ziprasidne hydrochloride to internal standard(carbamazepine),the regression equation was C=213Y-85.5(r=0.996 2).The results showed that ziprasidne has a good linear relationship in the range of 20.0-1200 μg.L-1.The average recovery of ziprasidne hydrochloride was 97.38%.CONCLUSION The method provides a simple and accurate way for clinical monitoring of ziprasidne hydrochloride in plasma.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2010年第10期939-941,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 高效液相色谱法 盐酸齐拉西酮 血药浓度 HPLC ziprasidne hydrochloride plasma concentration
  • 相关文献

参考文献10

  • 1封宇飞,雷静,吕俊玲,刘志鹤,李金娥.新型非典型抗精神病药齐拉西酮[J].中国新药杂志,2003,12(10):817-820. 被引量:42
  • 2OSAMA Y, AL-DIRBASHII, HASSAN Y, et al. Rapid liquid chromatography tandem mass spectrometry method for quantification of ziprasidone in human plasma [J]. Biomed Chromatogr, 2005, 20(4): 365-368.
  • 3SUCKOW R F, FEIN M, CORRELL C U, et al. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 799 (2): 201-208.
  • 4ARAVAGIRI M, MARDER S R, POLLOCK B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients [J]. J Chromatogr B, 2007, 847(2): 237-244.
  • 5ZHANG G D, TERRY A V, BARTLETT M G. Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry [J]. Biomed Chromatogr, 2008, 22(7): 770-778.
  • 6JULIA S, SEBASTIAN H, CHRISTOPH H. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection [J]. Therapeutic Drug Monitoring, 2005, 27(2): 158-162.
  • 7周臻,葛庆华,支晓瑾,马丽丽.人血浆中齐拉西酮的LC-MS/MS法测定[J].中国医药工业杂志,2008,39(3):203-205. 被引量:4
  • 8何海霞,周远大,唐竟,陈秋宇.高效液相色谱法测定人血浆中齐拉西酮浓度[J].药物分析杂志,2006,26(6):752-754. 被引量:11
  • 9ZHOUYD HEHX.Pharmacokinetics of ziprasidone tablet in healthy subjects .四川生理科学杂志,2004,26(4):166-167.
  • 10李华芳,沈一峰,葛庆华,顾牛范.盐酸齐拉西酮在中国健康志愿者中的药代动力学研究[J].上海精神医学,2006,18(4):222-225. 被引量:9

二级参考文献28

  • 1周远大,吴妍,何海霞.齐拉西酮片剂的人体药动学[J].中国新药与临床杂志,2006,25(2):95-97. 被引量:6
  • 2李华芳,沈一峰,葛庆华,顾牛范.盐酸齐拉西酮在中国健康志愿者中的药代动力学研究[J].上海精神医学,2006,18(4):222-225. 被引量:9
  • 3Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current herapeutics[ J ]. Curr Med Chem, 2002,9(5) : 521 - 548.
  • 4Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with aunique human receptor binding profile[ J ]. Eur J Pharmacol, 2001,425 (3) : 197 - 201.
  • 5Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multipledose pharrnacokinetics of 2iprasidone under non-fasting conditions in healthy male volunteers [ J ]. Br J Clin Pharmacol, 2000,49(Suppl 1) :S5 - S13.
  • 6Miceli JJ,Hunt T,Cole MJ, et al. The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration(abstract) [ J ]. Clin Pharmacol Ther, 1994,62 :142.
  • 7Prakash C,Kamel A,Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans[J].Drug Metab Dispos, 1997,25(7) :863 - 872.
  • 8Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multipledose pharmacokinetics of ziprasidone in healthy young and elderly volunteers[J]. Br J Clin Pharmacol,2000,49(Suppl 1 ) : S15 -S20.
  • 9Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function[J]. Br J Clin Pharmacol,2000,49(Suppl 1) :S27 - S33.
  • 10Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function[J]. Br J Clin Pharmacol, 2000,49 ( Suppl 1 ) : S21 -S26.

共引文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部